Depression is common, debilitating, and often difficult to treat. For many people, antidepressant medication is presented as a first-line solution. This raises an important and reasonable question: how effective are these medications in real-world clinical practice?
This article explores that question—not to dismiss antidepressants outright, but to place their benefits, limitations, and role in treatment into clearer perspective. Key sources are referenced throughout, with a selected evidence base provided at the end for readers who wish to explore the evidence in more detail.
Informed Consent and Expectations
When starting any medical treatment, patients should be given a realistic understanding of likely benefits, limitations, and potential side effects.
In the case of antidepressants, expectations are often framed in broad, optimistic terms. However, the clinical reality is more nuanced. Not all patients respond, and even among those who do, the degree of improvement varies considerably.
A central issue is remission—whether symptoms meaningfully resolve, not simply whether there is some improvement relative to placebo.
What Does the Evidence Actually Show?
Large meta-analyses demonstrate that antidepressants are more effective than placebo. However, the magnitude of this benefit is often modest, particularly in mild to moderate depression (Cipriani et al., 2018).
More detailed analyses suggest that clinically meaningful benefits are largely confined to individuals with more severe depression (Fournier et al., 2010; Kirsch et al., 2008).
This distinction is important. It suggests that while antidepressants have a role, their effectiveness is not uniform across the spectrum of depressive illness.
Real-World Effectiveness: The STAR*D Trial
The STAR*D trial remains one of the most informative large-scale studies of antidepressant effectiveness in real-world clinical settings.
The findings are instructive: approximately one-third of patients achieved remission after the first antidepressant (Rush et al., 2006). This also means that, for around two-thirds of patients, first-line treatment did not result in full remission.
The interpretation of STAR*D findings is not without controversy. Some researchers have argued that commonly cited remission rates may overestimate real-world effectiveness, particularly when accounting for patient dropout and the requirement for sustained remission. On more conservative analyses, the proportion of patients achieving sustained remission may be considerably lower—potentially in the region of 15–20%.
While these interpretations are debated, they reinforce an important clinical point: achieving sustained remission with antidepressant treatment alone is often more difficult than headline figures suggest.
Subsequent treatment steps in the STAR*D study improved outcomes for some, but with diminishing returns, increasing side effects, and higher dropout rates. This reflects a common clinical reality: antidepressants help some patients, but many do not achieve remission, even after multiple treatment attempts.
Interpreting the Evidence: Bias and Complexity
Interpreting antidepressant research is not straightforward. Concerns about publication bias have been well documented, with evidence showing that positive studies are more likely to be published than negative ones (Turner et al., 2008).
This does not invalidate the evidence base, but it does mean that headline findings should be interpreted with care.
The Role of Placebo Effects
A consistent finding across antidepressant trials is the substantial improvement observed in placebo groups.
Analyses of clinical trial data suggest that a large proportion of the improvement seen in patients taking antidepressants is also observed in those receiving placebo. For example, Kirsch and colleagues found that approximately 80% of the observed response to antidepressants was also seen in placebo groups (Kirsch et al., 2002). Similarly, a meta-analysis by Rief et al. (2009) reported that the placebo response accounted for a substantial proportion of the overall treatment effect.
These findings do not mean that antidepressants have no effect. Rather, they indicate that the specific pharmacological contribution of the drug—over and above placebo—is often relatively modest, particularly in mild to moderate depression (Kirsch et al., 2008).
This highlights an important point: improvement in depression is driven by multiple interacting factors, including expectation, therapeutic context, and natural variation in symptoms. Medication may contribute to this process, but it is rarely the sole driver of change.
Side Effects and Functional Impact
Antidepressants are generally considered safe, but they are not without cost.
Commonly reported side effects include emotional blunting, reduced motivation, fatigue, and sexual dysfunction. In some contexts—particularly neurorehabilitation—these effects can be clinically significant.
Recovery from brain injury or stroke often depends on motivation, emotional engagement, and active participation in therapy. Any intervention that dampens these capacities needs to be considered carefully.
A Balanced Perspective
Depression is heterogeneous, and responses to treatment vary widely. There is no question that some patients derive substantial benefit from antidepressant medication, particularly in cases of severe or recurrent depression. These benefits can be meaningful and, at times, life-changing.
At the same time, the broader evidence base suggests that many individuals—especially those with mild to moderate symptoms—experience limited clinical benefit (Jakobsen et al., 2017). In these cases, the routine use of antidepressants as a default first-line intervention warrants closer scrutiny.
The issue, therefore, is not whether antidepressants work at all, but whether they are being used in a way that reflects their true efficacy profile.
The Bigger Picture: Depression as a Systems Problem
Depression is not simply a “chemical imbalance” that can be corrected with a single intervention. It reflects disruptions across multiple interacting systems, including emotional regulation, cognitive processing, sleep, stress physiology, and behaviour.
From this perspective, medication can be helpful, but it is rarely sufficient on its own.
A more comprehensive approach includes psychological therapies, physical activity, sleep regulation, and broader brain health strategies. Emerging approaches such as vagus nerve stimulation (VNS) also offer new ways of targeting regulatory systems more directly.
So, Do Antidepressants Really Work?
The most accurate answer is:
- Antidepressants work for some people.
- Antidepressants do not work for many.
- And for most, antidepressants are only part of the solution.
Understanding this allows for more realistic expectations and more effective, individualised treatment strategies.
Where to from here?
If you’re struggling with depression, the most important point is that there are multiple pathways to recovery. Medication may play a role, but it is rarely the whole answer. A more effective approach often involves understanding how your brain is functioning as a system—how it regulates mood, energy, attention, and behaviour—and then targeting those processes in a structured way.
At Ormond Neuroscience, this is the basis of our Neuroharmonics approach. We focus on restoring regulation across brain systems using evidence-informed strategies tailored to the individual. This may include behavioural interventions, cognitive strategies, and, where appropriate, bioelectric neuromodulation such as vagus nerve stimulation (VNS), which is increasingly supported by research as a tool for improving mood regulation without many of the side effects associated with medication.
If you’re not getting the results you expected from antidepressants—or if you’re looking for a more comprehensive, personalised approach to managing depression—you’re welcome to get in touch. We’d be happy to discuss your situation and explore whether a Neuroharmonics-based programme, with or without VNS, might be appropriate for you.
Selected references and evidence base
Cipriani, A., Furukawa, T. A., Salanti, G., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder. The Lancet, 391(10128), 1357–1366. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32802-7/fulltext
Fournier, J. C., DeRubeis, R. J., Hollon, S. D., et al. (2010). Antidepressant drug effects and depression severity. JAMA, 303(1), 47–53. https://jamanetwork.com/journals/jama/article-abstract/185157
Jakobsen, J. C., Gluud, C., & Kirsch, I. (2023). The effects of antidepressants versus placebo on major depressive disorder. BMJ Open, 13, e063095. https://bmjopen.bmj.com/content/13/7/e063095.long
Jakobsen, J. C., Katakam, K. K., Schou, A., et al. (2017). SSRIs versus placebo in major depressive disorder. BMJ Open, 7(9), e014706. https://bmjopen.bmj.com/content/9/6/e024886
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., et al. (2008). Initial severity and antidepressant benefits. PLoS Medicine, 5(2), e45. https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030240
Kirsch, I., Moore, T. J., Scoboria, A., & Nicholls, S. S. (2002). The emperor’s new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prevention & Treatment, 5(1), Article 23.
https://psycnet.apa.org/record/2002-14079-003
Moncrieff, J., & Kirsch, I. (2005). Efficacy of antidepressants in adults. BMJ, 331(7509), 155–157. https://www.bmj.com/content/331/7509/155
Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010). Efficacy and effectiveness of antidepressants: Current status of research. Psychotherapy and Psychosomatics, 79(5), 267–279.
https://karger.com/pps/article/79/5/267/282500/Efficacy-and-Effectiveness-of-Antidepressants
Rief, W., Nestoriuc, Y., Weiss, S., et al. (2009). Meta-analysis of the placebo response in antidepressant trials. Journal of Affective Disorders, 118(1–3), 1–8. https://pubmed.ncbi.nlm.nih.gov/19246102/
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006). STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917. https://psychiatryonline.org/doi/10.1176/ajp.2006.163.11.1905
Turner, E. H., Matthews, A. M., Linardatos, E., et al. (2008). Selective publication of antidepressant trials. New England Journal of Medicine, 358(3), 252–260. https://www.nejm.org/doi/full/10.1056/NEJMsa065779
